These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6241769)

  • 1. Elimination of serum proteins and potential virus contaminants during hepatitis B vaccine preparation.
    Adamowicz P; Chabanier G; Hyafil F; Lucas G; Prunet P; Reculard P; Vinas R
    Vaccine; 1984 Sep; 2(3):209-14. PubMed ID: 6241769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large scale purification of hepatitis B surface antigen (HBsAg).
    Barin F; André M; Goudeau A; Coursaget P; Maupas P
    Ann Microbiol (Paris); 1978 Jul; 129B(1):87-100. PubMed ID: 718020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An affordable multideterminant plasma-derived hepatitis B virus vaccine.
    Prince AM; Vnek J; Brotman B
    IARC Sci Publ; 1984; (63):355-72. PubMed ID: 6085626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The preparation and safety of hepatitis B vaccine.
    Hilleman MR; McAleer WJ; Buynak EB; McLean AA
    J Infect; 1983 Jul; 7 Suppl 1():3-8. PubMed ID: 6674367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large-scale production of recombinant hepatitis B surface antigen from Pichia pastoris.
    Hardy E; Martínez E; Diago D; Díaz R; González D; Herrera L
    J Biotechnol; 2000 Feb; 77(2-3):157-67. PubMed ID: 10682276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Properties of recombinant hepatitis B vaccine.
    Ohmura T; Ohmizu A; Sumi A; Ohtani W; Uemura Y; Arimura H; Nishida M; Kohama Y; Okabe M; Mimura T
    Biochem Biophys Res Commun; 1987 Dec; 149(3):1172-8. PubMed ID: 2962578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma derivatives and viral hepatitis.
    Gerety RJ; Aronson DL
    Transfusion; 1982; 22(5):347-51. PubMed ID: 6812245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and potency aspects in the preparation of an experimental HBsAg vaccine.
    Thomssen R; Gerlich WH; Böttcher U; Legler K; Ritter S; Stibbe W; Weinmann W; Klinge O; Pfeifer U
    Dev Biol Stand; 1983; 54():23-31. PubMed ID: 6228464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Host cell protein testing strategy for hepatitis B antigen in Hexavalent vaccine - Towards a general testing strategy for recombinant vaccines.
    Toinon A; Fontaine C; Thion L; Gajewska B; Carpick B; Nougarede N; Uhlrich S
    Biologicals; 2018 Jul; 54():1-7. PubMed ID: 29861269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines made from recombinant yeast cells.
    Hilleman MR; Ellis R
    Vaccine; 1986 Jun; 4(2):75-6. PubMed ID: 3014772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality and safety of human hepatitis B vaccine.
    Hilleman MR; McAleer WJ; Buynak EB; McLean AA
    Dev Biol Stand; 1983; 54():3-12. PubMed ID: 6228470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification of hepatitis B surface antigen virus-like particles from recombinant Pichia pastoris and in vivo analysis of their immunogenic properties.
    Gurramkonda C; Zahid M; Nemani SK; Adnan A; Gudi SK; Khanna N; Ebensen T; Lünsdorf H; Guzmán CA; Rinas U
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Dec; 940():104-11. PubMed ID: 24141044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An efficacy trial of a mammalian cell-derived recombinant DNA hepatitis B vaccine in infants born to mothers positive for HBsAg, in Shanghai, China.
    Halliday ML; Kang LY; Rankin JG; Coates RA; Corey PN; Hu ZH; Zhou TK; Yuan GJ; Yao FL
    Int J Epidemiol; 1992 Jun; 21(3):564-73. PubMed ID: 1386063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of the hepatitis B vaccine. Inactivation of the AIDS virus during routine vaccine manufacture.
    Francis DP; Feorino PM; McDougal S; Warfield D; Getchell J; Cabradilla C; Tong M; Miller WJ; Schultz LD; Bailey FJ
    JAMA; 1986 Aug; 256(7):869-72. PubMed ID: 3016352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages.
    Whittle HC; Maine N; Pilkington J; Mendy M; Fortuin M; Bunn J; Allison L; Howard C; Hall A
    Lancet; 1995 Apr; 345(8957):1089-92. PubMed ID: 7715343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to hepatitis B vaccine in relation to the hepatitis B status of family members.
    Inskip HM; Hall AJ; Temple IK; Loik F; Herbage E; Chotard J; Whittle H
    Int J Epidemiol; 1991 Sep; 20(3):770-3. PubMed ID: 1835453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and PreS2 sequences.
    Tron F; Degos F; Bréchot C; Couroucé AM; Goudeau A; Marie FN; Adamowicz P; Saliou P; Laplanche A; Benhamou JP
    J Infect Dis; 1989 Aug; 160(2):199-204. PubMed ID: 2527274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immune response to hepatitis B vaccine in humans: inheritance patterns in families.
    Kruskall MS; Alper CA; Awdeh Z; Yunis EJ; Marcus-Bagley D
    J Exp Med; 1992 Feb; 175(2):495-502. PubMed ID: 1531063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-pot synthesis, purification, and formulation of bionanoparticle-CpG oligodeoxynucleotide hepatitis B surface antigen conjugate vaccine via tangential flow filtration.
    Raja K; McDonald R; Tuck S; Rodriguez R; Milley B; Traquina P
    Bioconjug Chem; 2007; 18(2):285-8. PubMed ID: 17302382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of pre-S2 peptide of hepatitis B virus: should it be in the vaccine?
    Hellström UB; Sylvan SP
    Prog Med Virol; 1988; 35():76-106. PubMed ID: 2971987
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.